<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="68759">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01789840</url>
  </required_header>
  <id_info>
    <org_study_id>BPH-P3-12-01</org_study_id>
    <secondary_id>2012-003446-33</secondary_id>
    <nct_id>NCT01789840</nct_id>
  </id_info>
  <brief_title>Prostate Artery Embolization With Embosphere Microspheres Compared to TURP for Benign Prostatic Hyperplasia</brief_title>
  <official_title>Prospective, Randomized, Controlled Investigation of Prostate Artery Embolization With Embosphere Microspheres Compared to Transurethral Resection of the Prostate for the Treatment of Symptomatic Benign Prostatic Hyperplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merit Medical Systems, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merit Medical Systems, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate improvement of symptoms from benign prostatic
      hyperplasia (BPH) as assessed by the International Prostate Symptom Score (IPSS) for
      prostatic artery embolization (PAE) using Embosphere Microspheres compared to conventional
      transurethral resection of the prostate (TURP).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>IPSS Score</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary endpoint will be improvement of symptoms from BPH evaluated using the IPSS at 12 months post procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization post procedure</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of post procedure catheterization</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall and procedure related adverse events</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety will be evaluated throughout the initial 12 months of the study by assessing adverse events, as well as changes in laboratory values, and finding on physical examination.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from baseline in peak urine flow rate (Qmax)</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in erectile function using the International Index of Erectile Function (IIEF)</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in mean prostate volume, as determine by MRI</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in post-void residual urinary volume (PVR)</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in detrusor muscle pressure (Pdet)</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Change in baseline from prostate specific antigen (PSA)</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">186</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Prostate artery emoblization (PAE)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prostate artery embolization using Embosphere Microspheres</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transurethral resection of the prostate (TURP)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Transurethral Resection of the Prostate (TURP)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Embosphere Microspheres</intervention_name>
    <arm_group_label>Prostate artery emoblization (PAE)</arm_group_label>
    <other_name>Embosphere Microspheres</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TURP</intervention_name>
    <arm_group_label>Transurethral resection of the prostate (TURP)</arm_group_label>
    <other_name>TURP - Transurethal resection of the prostate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient is age 50 to 79, inclusive

          2. Patient has signed informed consent

          3. Patient has had lower urinary tract symptoms (LUTS) secondary to BPH for at least 6
             months prior to study treatment

          4. Patient has a baseline IPSS Score &gt; 13 at baseline

          5. Patient has a prostate size of at least 50 grams and not more than 80 grams, measured
             by MRI

          6. Patient has BPH symptoms refractory to medical treatment or for whom medication is
             contraindicated, not tolerated or refused

          7. Patient must be a candidate for TURP

          8. Patient must meet ONE of the following criteria:

               -  Baseline Prostate Specific Antigen (PSA) &lt;2.5 ng/mL (no prostate biopsy
                  required)

               -  Baseline PSA &gt;2.5 ng/mL and ≤10 ng/mL AND free PSA &gt; 25% of total PSA (no
                  prostate biopsy required)

               -  Baseline PSA &gt;2.5 ng/mL and ≤10 ng/mL AND free PSA &lt; 25% of total PSA AND a
                  negative prostate biopsy result (minimum 12 core biopsy)

               -  Baseline PSA &gt;10 ng/mL AND a negative prostate biopsy (minimum 12 core biopsy)

        Exclusion Criteria:

          1. Active urinary tract infection

          2. Biopsy proven prostate or bladder cancer, or any cancer other than basal or squamous
             cell skin cancer

               -  The following patients must undergo prostate biopsy with a minimum of 12 cores
                  and have  a negative histopathology report to be enrolled in the study:

                    -  Patients with digital rectal examination (DRE) findings suspicious for
                       prostate cancer

                    -  Patients with baseline PSA levels &gt; 10 ng/mL

                    -  Patients with baseline PSA levels &gt;2.5 ng/mL and &lt; 10ng/mL AND free PSA &lt;
                       25% of total PSA

               -  Patients with cystoscopy findings suspicious for bladder cancer must undergo
                  biopsy and have a negative histopathology report to be enrolled in the study

          3. Bladder atonia, neurogenic bladder disorder or other neurological disorder that is
             impacting bladder function (eg multiple sclerosis, Parkinson's disease, spinal cord
             injuries, etc)

          4. Urethral stricture, bladder neck contracture, sphincter abnormalities, urinary
             obstruction due to causes other than BPH, or other potentially confounding bladder or
             urethral disease or condition

          5. Patient has taken beta blockers, antihistamines, anticonvulsants, or antispasmodics
             within 1 week of study treatment AND has not been on the same drug dosage for 6
             months with a stable voiding pattern

             • Dosage of these medications should not change during study participation unless
             medically necessary

          6. Patient has taken antidepressants, anticholinergics, androgens or
             gonadotropin-releasing hormonal analogues within 2 months of study treatment

          7. Patient has taken 5-alpha reductase inhibitors or alpha blockers within 1 month of
             study treatment

          8. Previous non-medical BPH treatment, including surgery, TURP, needle ablation,
             microwave or laser therapy, balloon dilation, stent implantation, or any other
             invasive treatment to the prostate

          9. Any known condition that limits catheter-based intervention or is a contraindication
             to embolization, such as intolerance to a vessel occlusion procedure or severe
             atherosclerosis.

         10. Patient is unable to stop taking anticoagulant, nonsteroidal antiinflammatory drug
             (NSAID) or anti-platelet therapy for 7 days prior to study treatment

         11. Unable to have MRI imaging (eg metal implant including pacemaker, replacement joint,
             etc)

         12. Patient has an asymmetric prostate, with &gt; 20% difference in size between lobes

         13. Cardiac condition  including congestive heart failure or arrhythmia, uncontrolled
             diabetes mellitus, significant respiratory disease or known immunosuppression which
             required hospitalization within the previous 6 months

         14. Baseline serum creatinine level &gt; 1.8 mg/dl

         15. Known upper tract renal disease

         16. Cystolithiasis or chronic hematuria within 3 months prior to study treatment

         17. Active prostatitis

         18. Previous rectal surgery other than hemorrhoidectomy, or history of rectal disease

         19. History of pelvic irradiation or radical pelvic surgery

         20. Patient is interested in future fertility

         21. Coagulation disturbances not normalized by medical treatment

         22. Acute urinary retention

         23. Known major iliac arterial occlusive disease

         24. Allergy to iodinated contrast agents

         25. Hypersensitivity to gelatin products
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francisco Cesar Carnevale, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Sao Paolo, Brazil</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Melodie Domurad, PhD</last_name>
    <phone>7816817900</phone>
    <email>BEST@merit.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>VA Greater Los Angeles Healthcare System</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shirley Mena</last_name>
      <email>shirley.mena@va.gov</email>
    </contact>
    <investigator>
      <last_name>Carol Bennett, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeremy Shelton, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Justin McWilliams, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hsin Yi-Lee, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>L. Tracy Paz, RN</last_name>
      <phone>650-723-0948</phone>
      <email>lp2@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel Sze, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Harsharan Gill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimiknu Mentore</last_name>
      <email>kimiknu.mentore@gunet.georgetown.edu</email>
    </contact>
    <investigator>
      <last_name>James Spies, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Keith Kowalcyzk, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rahul Patel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Holy Cross Hospital</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Miami VA Healthcare System</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Hyre</last_name>
      <email>michael.hyre@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Denizard</last_name>
      <phone>305-575-7000</phone>
      <phone_ext>3961</phone_ext>
      <email>jennifer.denizard@va.gov</email>
    </contact_backup>
    <investigator>
      <last_name>Shivank Bhatia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bruce Kava, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Issam Kably, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christopher Gomez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tampa General Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haydy Rojas, RN</last_name>
      <phone>813-892-0074</phone>
      <email>hrojas@tgh.org</email>
    </contact>
    <contact_backup>
      <last_name>Carmen Montanez</last_name>
      <phone>813-844-8558</phone>
      <email>cmontanez@tgh.org</email>
    </contact_backup>
    <investigator>
      <last_name>Clifford Davis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raviendar Bukkapatnam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Fabian</last_name>
      <email>efabian2@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Mark Lessne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephen Schatz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kelvin Hong, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Albany Medical Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara MacDowell, RN</last_name>
      <phone>518-262-5356</phone>
      <email>bmacdowell@communitycare.com</email>
    </contact>
    <contact_backup>
      <last_name>Brenda Romeo</last_name>
      <phone>518-262-8579</phone>
      <email>ccpurologyresearch@communitycare.com</email>
    </contact_backup>
    <investigator>
      <last_name>Gary Siskin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hugh Fisher, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Madeline Rosado, NP</last_name>
      <email>marosado@montefiore.org</email>
    </contact>
    <contact_backup>
      <last_name>Keila Martin, PA</last_name>
      <email>kemartin@montefiore.org</email>
    </contact_backup>
    <investigator>
      <last_name>Jacob Cynamon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lloyd Minsky, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lourdes Campos-Grundvig, RN</last_name>
      <phone>212-824-7877</phone>
      <email>lourdes.campos-grundvig@mountsinai.org</email>
    </contact>
    <investigator>
      <last_name>Aaron Fischman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Neil Grafstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas</name>
      <address>
        <city>Sao Paolo</city>
        <zip>05403</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Natalia Salvador</last_name>
      <email>natalia.delbiagi@hsl.org.br</email>
    </contact>
    <investigator>
      <last_name>Francesco Carnevale, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alberto Azoubel Antunes, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges-Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carol Dean</last_name>
      <email>carole.dean@egp.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Marc Sapoval, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas Thiounn, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Brazil</country>
    <country>France</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 28, 2014</lastchanged_date>
  <firstreceived_date>February 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BPH</keyword>
  <keyword>Prostate</keyword>
  <keyword>Prostatic Hyperplasia</keyword>
  <keyword>enlarged prostate</keyword>
  <keyword>LUTS</keyword>
  <keyword>urinary retention</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
